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AbstrACt
Objectives Pregnancy, menses and menopause are 
related to fluctuations in endogenous sex hormones in 
women, which cumulatively may alter cardiac electrical 
conduction. Therefore, we sought to study the association 
between number of pregnancies and reproductive period 
duration (RD, time from menarche to menopause) with 
ECG intervals in the Women’s Health Initiative Clinical 
Trials.
Design Secondary analysis of multicentre clinical trial.
setting USA.
Primary outcome measures ECGintervals: PR interval, 
P-wave duration, P-wave dispersion, QTc interval.
Participants n=40 687 women (mean age=62 years) 
participating in the Women’s Health Initiative Clinical Trials. 
82.5% were white, 9.3% black, 4% Hispanic and 2.7% 
Asian.
Methods In primary analysis, we employed multivariable 
linear regression models relating number of pregnancies 
and RD with millisecond changes in intervals from 
enrolment ECG. We studied effect modification by hormone 
therapy use.
results Among participants, 5+ live births versus 0 prior 
pregnancies was associated with a 1.32 ms increase in PR 
interval (95% CI 0.25 to 2.38), with a graded association 
with longer QTc interval (ms) (none (prior pregnancy, no 
live births)=0.66 (–0.56 to 1.88), 1=0.15 (–0.71 to 1.02), 
2–4=0.25 (–0.43 to 0.94) and 5+ live births=1.15 (0.33 
to 1.98), p=0.008). RD was associated with longer PR 
interval and maximum P-wave duration (but not P-wave 
dispersion) among never users of hormone therapy: (PR 
(ms) per additional RD year: 0.10 (0.04 to 0.16); higher 
P-wave duration (ms): 0.09 (0.06 to 0.12)). For every year 
increase in reproductive period, QTc decreased by 0.04 ms 
(−0.07 to –0.01).
Conclusions An increasing number of live births is 
related to increased and RD to decreased ventricular 
repolarisation time. Both grand multiparity and longer 
RD are related to increased atrial conduction time. 
Reproductive factors that alter midlife cardiac electrical 
conduction system remodelling in women may modestly 
influence cardiovascular disease risk in later life.
trial registration number NCT00000611; Post-results.
IntrODuCtIOn 
ECG parameters reflect current as well as future 
cardiovascular disease risk
ECG parameters are reflections of both 
current and future cardiovascular disease 
(CVD) risk. For example, in the Fram-
ingham Heart Study, a prolonged PR interval 
(>200 ms) (which is defined as the period, 
measured in milliseconds, that extends from 
the beginning of the P wave (the onset of 
atrial depolarisation) until the R wave), was 
related to incident atrial fibrillation, all-cause 
mortality and to the likelihood of needing 
a permanent pacemaker.1 In addition to PR 
interval, the P-wave duration (or the period 
in milliseconds during which the atrium 
depolarises) more directly relates to atrial 
size and is an antecedent of atrial fibrilla-
tion.2 Both PR interval and P-wave duration 
are markers of left atrial size which in turn is 
a correlate of hypertensive heart disease3 and 
incident stroke.4 P-wave dispersion, defined 
as the difference between the maximum and 
the minimum P-wave duration recorded from 
multiple different surface ECG leads, is an 
additional marker of atrial remodelling and 
strengths and limitations of this study
 ► A notable limitation is that the exposure variables 
were acquired retrospectively.
 ► A strength is the use of a well-characterised mul-
tiethnic, large data  set of postmenopausal women 
representative of women in the USA.
 ► We were unable to adjust for pregnancy complica-
tions such as pre-eclampsia or gestational diabetes.
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antecedent of atrial fibrillation.5 It is unclear to what 
extent PR interval, P-wave duration or P-wave dispersion 
are affected by premenopausal hormonal fluctuations 
from the menstrual cycle and childbearing.
Pregnancy, cardiac remodelling and the ECG
Pregnancy and the postpartum period both have substan-
tial physiological effects on cardiac electrophysiology. 
Physiological studies of women during early and late preg-
nancy as well as early post partum suggest a shortening of 
the corrected QT interval (QTc) which partially reverts 
back to pre-pregnancy values following post partum.6 7 
The QT interval is defined as the measure of time between 
the onset of ventricular depolarisation and completion 
of ventricular repolarisation, and because QT interval 
is strongly related to heart rate, the QTc is corrected for 
heart rate. Direct pathophysiological links connecting 
myocardial structural remodelling and cardiac electrical 
remodelling have been increasingly recognised.8 With 
regards to myocardial remodelling, pregnancy-induced 
cardiac remodelling does not completely revert back to 
pre-pregnancy levels and effects of increasing parity on 
cardiac remodelling can be detected even in midlife.9 
However, the extent to which an increasing number of 
pregnancies exerts long-lasting effects on the cardiac 
electrical conduction system is uncertain.9
Oestrogen exposure and the ECG
In addition to the more marked hormonal fluctuations 
seen during pregnancy, there are also more subtle, cyclic 
changes in oestrogen and progesterone cycling that 
occur during menstrual cycling in women of reproduc-
tive age. Testosterone and progesterone are recognised to 
decrease the QTc interval.10 Prior data from the Women’s 
Health Initiative (WHI) Hormone Trial suggests that 
oestrogen-only postmenopausal therapy modestly 
prolongs QTc beyond that of both oestrogen–progestin 
therapy and placebo.11 However, it is uncertain whether 
the premenopausal endogenous hormonal fluctuations 
(reflected by the length of the interval from menarche to 
menopause, and by number of pregnancies) are associ-
ated with changes in QTc in the WHI.
WHI represents a unique resource to study questions 
related to pregnancy and reproductive history and ECG 
parameters and thus we sought to determine if there is a 
positive or negative association between number of preg-
nancies and reproductive period duration with midlife 
ECG intervals (PR interval and QTc) and P-wave parame-
ters (P-wave maximum duration and dispersion).
MEthODs AnD AnAlysIs PlAn
Our current study design is a secondary analysis of a previ-
ously conducted set of clinical trials.
study sample
The WHI recruitment began in 1991 and consisted of 
a set of clinical trials/and an observational study on 
hormone therapy, dietary modification and calcium/
vitamin D supplementation on CVD, cancer and frac-
tures.12 The  clinicaltrial. gov identifier for the WHI is 
NCT00000611. At the time of enrolment, all women 
enrolled in the WHI were required to be between 50 and 
79 years of age, postmenopausal and intending to reside 
in the area for at least 3 years. Other enrolment criteria 
have been previously described.13 This analysis drew 
from the cohort of women enrolled in the WHI clinical 
trials (and not observational study), as WHI clinical trial 
participants have ECGs performed per protocol. Figure 1 
shows the creation of the study sample. Of 68 132 women 
in WHI studies (postmenopausal hormone therapy, diet 
and calcium/vitamin D and observational studies), we 
excluded 5217 who were missing ECGs and 15 543 who 
had prevalent CVD. Because number of pregnancies and 
reproductive period (in particular age at menopause) 
are known to be associated with later CVD and a history 
of CVD is related strongly with ECG changes including 
QTc and certainly increased PR, we sought to exclude 
women with a history of CVD in order to assess associa-
tions between reproductive period duration and number 
of pregnancies that were not directly mediated through 
CVD. Of these 47 372 women, 6685 were further excluded 
for having missing covariate data, leaving a final sample 
of included women equalling 40 687. In a missing impu-
tation sensitivity analysis described below, we additionally 
analysed the 6685 women with missing covariate data 
(total n=54 057).
Patient and public involvement
WHI was designed to address the gaps in knowledge 
about the major health issues in postmenopausal women. 
Patients assisted research staff in recruiting, and results 
for all measures done at the study examinations were 
explained to each participant. Major study results are 
communicated to participants via newsletters.
Figure 1 Creation of the study sample. Clinical trials include 
hormone trial, dietary modification and calcium/vitamin D. 
CVD, cardiovascular disease.
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Ascertainment of reproductive exposures
Information on reproductive factors was collected via 
questionnaire at the second screening visit in the WHI 
(between 1993 and 1998). Participants were asked how 
many times they had been pregnant (were given choices 
ranging from 0 to 8+), number of live births and how old 
they were at the end of the first and at the end of their last 
pregnancy (<20, 20–24, 25–29, 30–34, 35+years). In order 
to be able to also study women who had not experienced 
pregnancy and/or childbirth and in an effort to make 
our study as representative as possible, we separately 
categorised women who had had no prior pregnancies 
and women who had experienced a pregnancy but no 
live births (ie, due to miscarriage, stillbirth or abortion) 
as separate categories. We further categorised women 
based on our prior work demonstrating that having five 
or more pregnancies was associated with greater cardiac 
remodelling.9 Due to small cell sizes, we combined women 
with five or more pregnancies leading to live births into 
one category. Preliminary data analysis reflected that 2–4 
had similar effects sizes for PR and QTc and thus these 
categories were collapsed into a single category for ease 
of interpretation. Therefore, the exposure categories 
for number of pregnancies leading to live births were 
as follows: no pregnancies (referent), none (prior preg-
nancy, no live births), 1, 2–4, 5 or more. Age at menarche 
(<9, 10, 11, 12, 13, 14, 15, >16 years) and age at meno-
pause was asked on this screening questionnaire. Repro-
ductive period duration (RD) was defined as the duration 
between age at menarche to age at menopause (in years). 
Detailed current and prior hormone therapy (or post-
menopausal hormone replacement therapy) usage and 
hysterectomy/oophorectomy status was collected at 
enrolment and has been previously described.14 Ques-
tions regarding the use and duration of oral contracep-
tive usage were also collected at enrolment.
Ascertainment of covariates
Age, income, education, self-reported race/ethnicity, 
geographic region of the USA, history and duration of 
breast feeding were collected at participant enrolment 
and second screening examinations. Body mass index 
(BMI, kg/m2) was calculated using height and weight 
measured by study staff at baseline. Women with hyperten-
sion were identified as those with a self-reported history 
of treated hypertension or blood pressure measurements 
meeting JNC 7 criteria for hypertension.15 Diabetes was 
identified by self-reported use of antidiabetic medica-
tions and hyperlipidaemia by use of cholesterol-lowering 
medications.
ECG parameters
Standard 12-lead ECGs were recorded in all women by 
strictly standardised procedures in all clinical centres 
as has been described.16 All ECGs were processed in 
a central laboratory (EPICARE Center, University of 
Alberta, Edmonton, Canada, and later Wake Forest 
University, Winston-Salem, North Carolina, USA), where 
they were visually inspected for technical errors and 
inadequate quality. ECGs were processed with the 2001 
version of the Marquette 12-SL program (GE Marquette). 
In addition to PR and QT intervals, we also examined the 
maximum P-wave duration and dispersion (from all 12 
leads of the ECG).2 The QT interval was corrected using 
Bazett’s formula. 
statistical methods
Primary analysis
We employed multivariable linear regression to assess the 
association between reproductive exposures (number 
of pregnancies and RD) with the dependent variable 
of ECG parameters (PR interval in milliseconds, P-wave 
duration, P-wave dispersion, QTc in milliseconds). Multi-
variable models were adjusted for a priori covariates: 
age, BMI, hypertension status, diabetes, income, educa-
tion, race/ethnicity, region, history of breast feeding, 
antianxiety medication, antidepressant medication, lipid 
medication, duration of breast feeding, oophorectomy 
status, hormone therapy use, heart rate and QRS dura-
tion. In analyses considering categories of live births, we 
employed a linear trend test.
We explored effect modification of the primary expo-
sures, number of live births and RD, by hormone therapy 
usage and hysterectomy status. We classified hormone 
therapy usage into three categories: women who reported 
current, prior or no hormone therapy usage. A statistical 
interaction term between hormone therapy usage and 
the exposure (RD or number of live births) was used 
to consider effect modification by reported hormone 
therapy use. When the statistical interaction term was 
statistically significant (p<0.05) according to a likelihood 
ratio test, we presented the estimates in each of the three 
categories of hormone therapy use and we presented a 
single estimate if there was no evidence for effect modi-
fication by hormone therapy. A similar approach was 
employed for studying RD or number of live births and 
hysterectomy status. To show sensitivity of estimates to 
confounders, unadjusted associations were reported as 
well as those associations adjusted for the confounders 
listed above.
Secondary analyses
In secondary analyses, we removed subjects who reported 
never being pregnant and used multivariable linear 
regression to model associations between age at first live 
birth and the five ECG measures. These models used 
the same covariates to adjust association as those in our 
primary analyses. Subjects who had implausible secondary 
outcome values (ie, all zero values or all constant values 
across all ECG measures) were removed. We addition-
ally adjusted for covariates that we were concerned may 
have confounded the associations between exposure and 
dependent variables in our study. We additionally fit addi-
tional models which included both RD and number of 
pregnancies to ensure that one exposure did not alter the 
other’s association with the dependent variables. Given 
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that anxiety and depression could affect both exposure 
and dependent variables in our study, we further adjusted 
for use of these medications. Antianxiety and antidepres-
sant medication use (selective serotonin reuptake inhibi-
tors (SSRIs) and non-SSRI) were recorded on enrolment 
by nurse examination of medication bottles. Medications 
were classified according to the National Drug Index clas-
sification system. We adjusted for Ca/vitamin D status, 
oral contraceptive usage (yes/no and duration or usage). 
We further adjusted for menstrual irregularities/fertility 
disorders/and endometriosis, which are also related to 
hormonal fluctuations in women.
Multiple imputation analyses
There were n=6685 women in our study with missing 
covariate data. We used multiple imputation techniques 
to impute missing covariates and refit models from 
primary analyses to explore the sensitivity of our results to 
missing data. We used the PROC MI in SAS to construct 
20 multiply imputed data sets. Missing variables were 
imputed via fully conditional specification method in 
PROC MI using all variables from the analytic model. 
We fit models to each imputed data set and pooled the 
results. The pooled results from imputation did not differ 
appreciably from the results of the complete case analysis 
(data not shown).
All analyses were performed in SAS V.9.4 (SAS Institute).
rEsults
Table 1 shows the baseline characteristics of our sample 
including women who were included in our study and 
those excluded from analysis for missing variables. Data 
are displayed by number of pregnancies lasting at least 
6 months. The mean age at enrolment was 62.4 years, 
while the mean age at menarche was 12.6 and mean 
age at menopause was 50.0 years. 82.5% of women were 
white, 9.3% black, 4% Hispanic and 2.7% Asian. Forty-
five per cent of the study sample reported never having 
used hormone therapy prior to enrolment.
Pr interval
Compared with women reporting never having been 
pregnant, having five or more pregnancies was associ-
ated with a 1.3 ms longer PR interval (table 2). Among 
women who reported never having used hormones, each 
additional year of reported reproductive period duration 
was associated with a 0.1 ms longer PR interval (or atrial 
conduction velocity). Conversely, there was no significant 
association between RD and PR interval among women 
who reported prior or current hormone therapy use (p 
value for interaction <0.01) (table 2). Age at first live 
birth was not related to PR interval (data not shown).
Qtc
Compared with never having been pregnant, having five 
or more pregnancies was related to a 1.2 ms longer QTc 
(table 3). However, not carrying a pregnancy to term, 
or having 1 or 2–4 term pregnancies (vs not being preg-
nant), were not related to QTc. For each additional year in 
reproductive period duration, there was a 0.4 ms shorter 
QTc (table 3). Restricting to women who had at least one 
live birth did not change our results (data not shown).
P-wave duration and dispersion
P-wave dispersion was higher for women with 2–4 live 
births (ms increase=0.62, 95% CI 0.01 to 1.24) and 5 live 
births (0.94, 95% CI 0.20 to 1.67) compared with those 
who reported never having been pregnant (table 4). 
Reproductive period duration was related to maximum 
P-wave duration among women who reported never 
having used hormones (0.09, 95% CI 0.06 to 0.13) but 
not among those who reported prior or current hormone 
therapy use (p interaction <0.01) (table 5).
Secondary results
Models that contained both RD and number of preg-
nancies together were not materially different (data not 
shown). Further adjustment for antidepressants and anti-
anxiety medications did not materially affect our results. 
Further adjustment for Ca and vitamin D status or oral 
contraceptive use, and/or duration did not materially 
affect our results. Further adjustment for menstrual irreg-
ularities/fertility disorders/and endometriosis did not 
materially change our results.
DIsCussIOn
summary of findings
We found that having five or more pregnancies compared 
with none was associated with a small increase in midlife 
atrial conduction time, independent of factors known to 
be associated with this interval (PR). Number of live births 
among women with at least one live birth (compared with 
no prior pregnancies) was associated with increased atrial 
conduction time. Having five or more pregnancies was 
related to a small increase in ventricular repolarisation 
time compared with having no prior pregnancies. Among 
women reporting no prior exogenous hormone use, 
each additional year of reported RD was related to a very 
modest (0.1 ms) longer atrial conduction time. RD was 
related to a very modest increase in P-wave duration. RD 
was related to a shorter ventricular repolarisation time.
Mechanisms linking pregnancy and atrial electrical 
remodelling
The effect of cumulative pregnancies on midlife ECGs 
would likely result from both (1) the pregnancy itself and 
(2) incident cardiometabolic factors that are impacted 
by pregnancy such as adiposity17 and vascular stiffness,18 
and premenopausal blood pressure.19 Adiposity and 
blood pressure are related to increased P-wave indices in 
a normal healthy population,20 and these P-wave indices 
are ECG reflections of increased left atrial pressure, size 
and potentially fibrosis. The period of pregnancy and 
the peripartum are characterised by hormonal changes 
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that affect both cardiovascular haemodynamics and 
adaptive myocardial remodelling.21 Pregnancy causes 
increased cardiac output, increased left ventricular mass 
and decreased systemic vascular resistance.22 The uterus 
and placenta in support of the growing fetus and fetal 
circulatory system represent a significant vascular shunt 
which contributes to these haemodynamic adaptations in 
pregnancy.22 The sum of these changes results in both left 
atrial and left ventricular dilation. However, the effects of 
normal pregnancy on electrographic remodelling during 
pregnancy are not well described. A prior small clinical 
study has looked at P-wave duration and P-wave disper-
sion among pregnant women compared with controls 
and found that both of these parameters are increased.23
Pregnancy and cumulative effects on ventricular 
repolarisation
A prior study in 37 women in late pregnancy compared with 
18 age-matched controls demonstrated that QTc substan-
tially prolongs late in pregnancy and that this only partially 
Table 2 Unadjusted and multivariable-adjusted association of number of pregnancies leading to live births and reproductive 
period duration with PR interval (ms) in n=40 687 women in the Women’s Health Initiative Clinical Trials
Unadjusted
effect (95% CI)
Multivariable-adjusted
effect* (95% CI)
Number of live births and reproductive period duration are each in their own separate multivariable models
Number of live births (categorical with never pregnant as 
referent category)
P value for linear 
trend=0.11
  Never pregnant Ref. Ref.
  None (prior pregnancy, no live births) 1.44 (−0.18 to 3.06) 1.15 (−0.43 to  2.74)
  1 1.16 (0.04 to 2.28) 0.54 (−0.57 to 1.66)
  2–4 1.20 (0.34 to 2.05) 0.59 (−0.301 to 1.48)
  5+ 3.06 (2.07 to 4.06) 1.32 (0.25 to 2.39)
Due to the fact that there was statistically significant effect modification by HT use on the association between reproductive 
period and PR interval in linear regression models, we present the model estimates by strata of HT use
Reproductive period duration (continuous, years) P value for 
interaction=0.009
  Never HT user 0.05 (−0.01 to 0.11) 0.10 (0.04 to 0.16)
  Past HT use 0.002 (−0.07 to 0.08) 0.08 (−0.00 to 0.15)
  Current HT use −0.09 (−0.15 to to 0.03) −0.02 (−0.08 to  0.04)
*Covariates include age, baseline BMI, baseline hypertension status, history of diabetes, income, education, race/ethnicity, region, history/
duration of breast feeding, lipid medication, oophorectomy status, hysterectomy status, hormone use history, heart rate and QRS duration.
BMI, body mass index; HT, hormone therapy.
Table 3 Unadjusted and multivariable-adjusted association of number of pregnancies leading to live births and reproductive 
period duration with QTc interval (ms) in n=40 687 women in the Women’s Health Initiative and Clinical Trials
Unadjusted
effect (95% CI)
Multivariable-adjusted
effect* (95% CI) P values
Number of live births and reproductive period duration are each in their own multivariable models
Number of live births (categorical with 
never pregnant as referent category)
P value for linear 
trend=0.008
  Never pregnant Ref. Ref.
  None (prior pregnancy, no live births) 0.54 (−0.76 to 1.83) 0.66 (−0.56 to 1.88)
  1 0.29 (−0.60 to 1.18) 0.15 (−0.71 to 1.02)
  2–4 0.63 (−0.05 to 1.31) 0.25 (−0.43 to 0.94)
  5+ 2.39 (1.59 to 3.19) 1.15 (0.33 to 1.98)
Reproductive period duration (continuous, years) −0.09 (−0.12 to 0.06) −0.04 (−0.07 to 0.01) P value=0.01
*Covariates for number of live births analysis include age, baseline BMI, baseline hypertension status, history of diabetes, income, education, 
race/ethnicity, region, history/duration of breast feeding, lipid medication, oophorectomy status, hysterectomy status, hormone use history, 
heart rate and QRS duration. Covariates for reproductive period duration analysis include live births, age, baseline BMI, baseline hypertension 
status, history of diabetes, income, education, race/ethnicity, region, history of breast feeding, duration of breast feeding, lipid medication, 
oophorectomy status, hysterectomy status, hormone use history and QRS duration.
BMI, body mass index; HT, hormone therapy.
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corrects back to pre pregnancy values post partum.7 Our 
finding that having five or more pregnancies compared 
with no prior pregnancies suggests that QTc prolonga-
tion during pregnancy may accumulate across succes-
sive pregnancies and will be significantly increased on 
midlife ECG. Furthermore, we found evidence for a dose–
response relationship between number of pregnancies and 
midlife QTc. Cardiac electrical remodelling often reflects 
myocardial remodelling. We previously demonstrated that 
an increasing number of pregnancies were related to left 
ventricular volume increase and increase in left ventricular 
mass in a multiethnic cohort of women.9 The increase in 
cardiac volume and mass were more marked in grand multi-
para’s or women who had five or more pregnancies leading 
to live births.9 It is important to note that grand multiparity 
is less common with declining parity levels in the USA.
Table 4 Unadjusted and multivariable-adjusted associations between number of pregnancies leading to live births with 
P-wave duration and P-wave dispersion in n=39 338* women in the Women’s Health Initiative and Clinical Trials
Dependent variable
Number of
live births
Unadjusted
effect (95% CI)
Adjusted
effect (95% CI) P values
P-wave duration (ms) P value for linear trend
=0.73
Never pregnant Ref. Ref.
None (prior pregnancy, 
no live births)
0.09 (−0.73 to 0.92) 0.09 (−0.69 to 0.87)
1 −0.06 (−0.63 to 0.51) −0.20 (−0.76 to 0.35)
2–4 −0.03 (−0.47 to 0.40) −0.26 (−0.70 to 0.18)
5+ 0.99 (0.49 to 1.50) −0.22 (−0.74 to 0.31)
P-wave dispersion (ms) P for linear trend=0.13
Never pregnant Ref. Ref.
None (prior pregnancy, 
no live births)
0.67 (−0.42 to 1.77) 0.64 (−0.45 to 1.72)
1 0.44 (−0.32 to 1.20) 0.34 (−0.42 to 1.11)
2–4 0.72 (0.15 to 1.30) 0.62 (0.01 to 1.24)
5+ 1.49 (0.82 to 2.17) 0.94 (0.20 to 1.67)
Effect estimates correspond to expected millisecond increase in the specified interval measure for each parity group relative to the never 
pregnant group. Fully adjusted models were adjusted for age, baseline BMI, baseline hypertension status, history of diabetes, income, 
education, race/ethnicity, region, history of breast feeding, antianxiety medication, antidepressant medication, lipid medication, duration of 
breast feeding, oophorectomy status, hysterectomy status, hormone use history, heart rate and QRS duration.
*n differs from main analyses due to the exclusion of women with implausible PR wave measures.
BMI, body mass index.
Table 5 Reproductive duration and P-wave duration and dispersion by hormone use status in n=31 538* women in the 
Women’s Health Initiative Clinical Trial
Dependent variable Hormone use status
Unadjusted
effect (95% CI)
Adjusted
effect (95% CI) P values
Due to the fact that there was statistically significant effect modification by HT use on the association between reproductive 
period and P-wave duration in linear regression models, we present the model estimates by strata of HT use
P-wave duration (ms) Never user 0.07 (0.03 to 0.11) 0.09 (0.06 to 0.13) P value for interaction=
0.0009Past −0.04 (−0.08 to 0.005) 0.01 (−0.03 to 0.05)
Current −0.03 (−0.06 to 0.004) 0.01 (−0.02 to 0.05)
P-wave dispersion (ms) Never user 0.002 (−0.04 to 0.05) 0.01 (−0.03 to 0.06) P value for interaction=
0.65Past −0.03 (−0.09 to 0.02) −0.01 (−0.06 to 0.05)
Current −0.04 (−0.08 to 0.003) −0.02 (−0.06 to 0.03)
Effect estimates correspond to expected milliseconds increase in PR measure. These models contained an interaction term for reproductive 
period duration hormone use status. Fully adjusted models were adjusted for number of live births, age, baseline BMI, baseline hypertension 
status, history of diabetes, income, education, race/ethnicity, region, history of breast feeding, duration of breast feeding, antianxiety 
medication, antidepressant medication, lipid medication, oophorectomy status, hysterectomy status, hormone use history, heart rate and 
QRS duration.
*n differs from main analyses due to the exclusion of women with implausible PR-wave measures.
BMI, body mass index; HT,  hormone  therapy. 
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reproductive period duration and atrial conduction
The menstrual cycle consists of a relatively well-described 
hormone cycling in women consisting of both oestrogen 
and progesterone as well as testosterone production. A 
longer reproductive period duration reflects the cumula-
tive exposure that a woman has to these endogenous fluc-
tuations in sex hormone levels. Indeed, prior studies have 
assessed P-wave parameters throughout the menstrual 
cycle and noted that P-wave duration is substantially 
increased in the luteal phase.24 Among women who did 
report taking prior hormone therapy, we observed a very 
modest but significant increase in midlife PR interval and 
in P-wave duration. Exogenous hormone therapy use may 
obscure the relationship between endogenous hormone 
exposure from a longer reproductive period duration 
and P-wave parameters, which would explain our findings 
of effect modification by hormone therapy use. An earlier 
age at menarche (which would be related to increased 
reproductive period duration) has been associated with 
increased adiposity25 and diabetes,26 which in turn have 
been linked with increased P-wave duration2 and, in the 
case of BMI, with increased left atrial remodelling27 and 
thus may also partially underlie our findings.
reproductive duration and decrease ventricular repolarisation 
time
The QTc is shortened by the action of progesterone 
and lengthened by oestrogen during normal menstrual 
cycling. The net effect of these changes during a single 
menstrual cycle can result in shortening of ventricular 
repolarisation time or QTc.28 This is consistent with 
our finding that an incresed reproductive duration was 
modestly inversly related to QTc in WHI. Underlying 
these findings may be that increasing exposure to proges-
terone, in particular during menstrual cycling, may have 
cumulative and measurable effects on the midlife ECG in 
women.
Clinical relevance of our findings
The PR interval normally ranges from 120 to 200 ms in 
duration. Therefore, our finding that having five or more 
live births versus never having been pregnant was associ-
ated with an adjusted increase in PR interval of 1.32 ms,has 
modest clinical significance. For an individual with a PR 
interval at the upper limits of normal, 1.32 ms may be 
more clinically relevant in terms of the increased risks of 
later CVDs with PR >200 ms.1 The association of number 
of pregnancies leading to live births with QTc (with five 
or more pregnancies leading to live births having a 1.15 
ms increase in QTc compared with nulligravid women) is 
similarly modest with a normal QTc ranging from ~350 to 
460 ms in women. The effect sizes for reproductive dura-
tion were even more modest in size than those for P-wave 
indices and therefore likely have more relevance in terms 
of uncovering novel biological mechanisms related to 
cardiac electrical remodelling rather than reflecting clin-
ically significant differences among individuals.
strengths and limitations
The use of a well-characterised multiethnic, large data set 
of postmenopausal women representative of women 
in the USA is a strength of our study. A notable limita-
tion is potential recall bias since the exposure variables 
were acquired retrospectively and some are very distant 
events (eg, age at menarche occurred 40–70 years in the 
past). We were unable to adjust for pregnancy complica-
tions such as pre-eclampsia or gestational diabetes since 
these were not collected. We did not adjust for smoking, 
physical activity and habitual consumption of alcohol 
and coffee which may have been related to the exposure 
variables but are not widely known to be related to the 
ECG-dependent variables studied. We studied number 
of pregnancies in a categorical fashion and were unable, 
due to data constraints, to look at number of pregnancies 
as a continuous variables.
Directions for future research
Future studies that disentangle specific hormonal and 
molecular mechanisms that underlie the association 
demonstrated in our study will help us better under-
stand our study findings. Understanding which specific 
fertility factors alter electrical remodelling in women is an 
important direction for future research.
Conclusions
We found that having five or more pregnancies leading 
to live births compared with never having been preg-
nant is related to small but significant changes in atrial 
conduction time and ventricular repolarisation time. 
A longer reproductive period duration in women not 
exposed to exogenous hormone therapy is related to 
a modest increase in atrial conduction time and to a 
modest decrease in ventricular repolarisation. Reproduc-
tive health factors reflective of endogenous sex hormone 
exposure may be significant determinants of cardiac elec-
trical remodelling in midlife.
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